bluuebunny/crossref_metadata_2025 huggingface dataset:
Suppl. Table 2 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

Peptide information of potential T cell target antigens, tested by IFN-Î³ ELISpot
Suppl. Figure 9 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

(A) IFN-ð�›¾ ELISpot raw data of all HLA-A*02:01 patients analyzed (n = 7) showing the IFN-ð�›¾ spots / 1x105 T-cells for patient cells against TAAs vs. patient cells against the negative control (human immunodeficiency virus (HIV) gag/pol, 9 amino acids). Grey bars indicate a significantly increased immunogenicity compared to negative control (solid line). (B) Homogenous levels of stimulation while comparing the total immune response by mean of IFN-ð�›¾ spot numbers among astrocytomas (red) and oligodendrogliomas (blue) to a certain reactive epitope. (n.s., not significant, *, p < 0.05; **, p < 0.01)
Table S6 from miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Authors: Pekow Joel , Meckel Katherine , Dougherty Urszula , Huang Yong , Chen Xindi , Almoghrabi Anas , Mustafi Reba , Ayaloglu-Butun Fatma , Deng Zifeng , Haider Haider I. , Hart John , Rubin David T. , Kwon John H. , Bissonnette Marc
Published: April 2023

Significantly Differentially Expressed miRNAs between nUCaN and UC
Table S4 from miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Authors: Pekow Joel , Meckel Katherine , Dougherty Urszula , Huang Yong , Chen Xindi , Almoghrabi Anas , Mustafi Reba , Ayaloglu-Butun Fatma , Deng Zifeng , Haider Haider I. , Hart John , Rubin David T. , Kwon John H. , Bissonnette Marc
Published: April 2023

Significantly Differentially Expressed miRNAs between nUCaN and Normal
Figure S1 from miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Authors: Pekow Joel , Meckel Katherine , Dougherty Urszula , Huang Yong , Chen Xindi , Almoghrabi Anas , Mustafi Reba , Ayaloglu-Butun Fatma , Deng Zifeng , Haider Haider I. , Hart John , Rubin David T. , Kwon John H. , Bissonnette Marc
Published: April 2023

Supplementary Figure 1. IL17RD potentiates EGF-induced EGFR signaling. A) Cellular proliferation of HT29 and HCT116 cells 96 hours after transfection with a plasmid encoding IL-17RD compared to an EV plasmid. B) Cellular proliferation of HT29 and HCT116 cells treated with EGF for 96 hrs following transfection with a plasmid encoding IL-17RD or EV plasmid. C) pEGFR, EGFR, pAKT, and pERK expression in HT29 cells 15 minutes after treatment with EGF ( ) or media without EGF (-) and transfected with Flag-tagged IL17RD, EV plasmid, or no transfection (vehicle) (representative images of two blots containing 3 samples per group). D) pAKT expression in HT29 cells 30 minutes after treatment with media with or without EGF and transfected with a Flag-tagged IL17RD plasmid or EV plasmid. E) EGFR expression in untreated cells 96 hours after transfection with IL17RD.
Table S4 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Authors: Rogers Laura M. , Mott Sarah L. , Smith Brian J. , Link Brian K. , Sahin Deniz , Weiner George J.
Published: April 2023

GAUSS protein and PFS
Figure S3 from Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Authors: Ibrahimpasic Tihana , Xu Bin , Landa Iñigo , Dogan Snjezana , Middha Sumit , Seshan Venkatraman , Deraje Shyam , Carlson Diane L. , Migliacci Jocelyn , Knauf Jeffrey A. , Untch Brian , Berger Michael F. , Morris Luc , Tuttle R. Michael , Chan Timothy , Fagin James A. , Ghossein Ronald , Ganly Ian
Published: April 2023

Comparison of the most commonly mutated genes in fatal WDTC compared to nonfatal WDTC (TCGA)is shown in (A). Comparison of the most commonly mutated genes in fatal PDTC compared to nonfatal PDTC is shown in (B).
Figure S2 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Authors: Rogers Laura M. , Mott Sarah L. , Smith Brian J. , Link Brian K. , Sahin Deniz , Weiner George J.
Published: April 2023

GAUSS progression free survival by genotype
Figure S1 from Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Authors: Ibrahimpasic Tihana , Xu Bin , Landa Iñigo , Dogan Snjezana , Middha Sumit , Seshan Venkatraman , Deraje Shyam , Carlson Diane L. , Migliacci Jocelyn , Knauf Jeffrey A. , Untch Brian , Berger Michael F. , Morris Luc , Tuttle R. Michael , Chan Timothy , Fagin James A. , Ghossein Ronald , Ganly Ian
Published: April 2023

EIF1AX mutations in fatal non-anaplastic thyroid cancer.
Supplementary Tables from miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5
Authors: Stiegelbauer Verena , Vychytilova-Faltejskova Petra , Karbiener Michael , Pehserl Anna-Maria , Reicher Andreas , Resel Margit , Heitzer Ellen , Ivan Cristina , Bullock Marc , Ling Hui , Deutsch Alexander , Wulf-Goldenberg Annika , Adiprasito Jan Basri , Stoeger Herbert , Haybaeck Johannes , Svoboda Marek , Stotz Michael , Hoefler Gerald , Slaby Ondrej , Calin George Adrian , Gerger Armin , Pichler Martin
Published: April 2023

Supplementary Table 1: Primer sequences used for qRT PCR analysis Supplementary Table 2; Summary and comparison of clinico-pathological characteristics of the colorectal cancer patients in cohort 1 (n = 110) and cohort 2 (n = 182). Supplementary table 3 Univariate analysis of clinico-pathological parameters for the prediction of 5-years overall survival in patients with colorectal cancer in cohort 1 (n=110) and cohort 2 (n=182). Supplementary Table 4 Multivariate analysis of clinico-pathological parameters for the prediction of 5-years overall survival in patients with colorectal cancer in cohort 1 (n=110) and cohort 2 (n=182). Supplementary table 5: Up- and downregulated transcripts obtained from a microarray whole transcriptome profiling analysis in three independent biological replicates comparing the HCT116 miR-196b-5p stably overexpressing cells against control cells Supplementary Table 6: Down-regulated genes identified in the microarray analysis underwent in silico target prediction analysis according to the details described in the methods section. The table shows only downregulated genes with potentially miR-196b-5p interaction sites.
Supplemental Figures from Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast Interactions during Collective Invasion
Authors: Richardson Alessandra M. , Havel Lauren S. , Koyen Allyson E. , Konen Jessica M. , Shupe John , Wiles W.G. , Martin W. David , Grossniklaus Hans E. , Sica Gabriel , Gilbert-Ross Melissa , Marcus Adam I.
Published: April 2023

GEMM schematic, Kaplan-meier curve, vimentin antibody validation, immunoprofile of CIPs, quantification of vimentin IHC of patient samples
Supplemental Tables from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
Authors: Exley Mark A. , Friedlander Phillip , Alatrakchi Nadia , Vriend Lianne , Yue Simon , Sasada Tetsuro , Zeng Wanyong , Mizukami Yo , Clark Justice , Nemer David , LeClair Kenneth , Canning Christine , Daley Heather , Dranoff Glenn , Giobbie-Hurder Anita , Hodi F. Stephen , Ritz Jerome , Balk Steven P.
Published: April 2023

Supplemental Tables
Supplementary Figures 1-14, Supplementary Table 1-3 from Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer
Authors: Bachmayr-Heyda Anna , Aust Stefanie , Auer Katharina , Meier Samuel M. , Schmetterer Klaus G. , Dekan Sabine , Gerner Christopher , Pils Dietmar
Published: April 2023

Figure S1. Scheme of used methods (top box) and samples (colored bars) and obtained results; Figure S2. Correlations of median serum concentrations of metabolite classes of 62 healthy controls and 65 HGSOC patients; Figure S3. Boxplot of median concentrations of metabolite classes and glutamine and sum of hexoses (mainly glucose) divided in healthy controls and groups of different three year survivals; Figure S5. Boxplots of overall survival association-values of 19 amino acids, grouped according different physicochemical characteristics or according essential and non-essential for humans (red box); Figure S6. Median concentrations of GPhLs with different degrees of unsaturation in controls and patients with different three year survivals; Figure S7. Correlations of the GPhL score with nutritional measures, body mass index (BMI), and the Eastern Cooperative Oncology Group (ECOG) performance status; Figure S8. Correlations of the GPhL score ("Ascites"), low density protein (LDL), and the mean concentrations of other metabolite groups (non-significant glycerophospholipids (GPhLs), significant and non-significant with OS associated amino acids (AAs), and acylcarnitines) with ascites. (p-values, trend tests); Figure S9. Correlations of the GPhL score with the percentages of PD-L1 expressing tumor cells, PDL1 expressing tumor infiltrating immune cells, and intraepithelial CD8 positive immune cells; Figure S10. Histograms of correlation coefficients between serum and ascites GPhL concentrations; Figure S11. Targeted metabolomics of tumor tissues and correlations with matched serum samples; Figure S12. Targeted metabolomics of follow-up sera from 19 patients; Figure S13. KEGG pathways in HGSOC cancer cells, significantly associated with the GPhL score; Figure S14. Cyto- and chemokines correlated to the GPhL score in serum and ascites; Table S1. Characteristics of all high grade serous ovarian cancer patients and sub-cohorts used for various analyses and of healthy controls; Table S2. Univariate (corrected for tissue type) and multiple linear regression analyses between the GPhL score and immune checkpoint measures; Table S3. SPIA pathway analysis with 2,054 significant genes (FDR <20%) associated with the GPhL score (pSize, number of genes in pathway; NDE number of pathway genes in significant gene list).
supplementary Table S3 from BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Authors: Barras David , Missiaglia Edoardo , Wirapati Pratyaksha , Sieber Oliver M. , Jorissen Robert N. , Love Chris , Molloy Peter L. , Jones Ian T. , McLaughlin Stephen , Gibbs Peter , Guinney Justin , Simon Iris M. , Roth Arnaud D. , Bosman Fred T. , Tejpar Sabine , Delorenzi Mauro
Published: April 2023

Association of BM subtyping with known clinical features.
Supplementary information from Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors
Authors: Poulsen Thomas Tuxen , Grandal Michael Monrad , Skartved Niels Jørgen Østergaard , Hald Rikke , Alifrangis Lene , Koefoed Klaus , Lindsted Trine , Fröhlich Camilla , Pollmann Sofie Ellebæk , Eriksen Karsten Wessel , Dahlman Anna , Jacobsen Helle Jane , Bouquin Thomas , Pedersen Mikkel Wandahl , Horak Ivan David , Lantto Johan , Kragh Michael
Published: April 2023

Supplementary Materials and Methods and Figure Legends
Supplementary Table 8-9 from Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Authors: Liu Hao , Naxerova Kamila , Pinter Matthias , Incio Joao , Lee Hang , Shigeta Kohei , Ho William W. , Crain Jonathan A. , Jacobson Alex , Michelakos Theodoros , Dias-Santos Daniella , Zanconato Andrea , Hong Theodore S. , Clark Jeffrey W. , Murphy Janet E. , Ryan David P. , Deshpande Vikram , Lillemoe Keith D. , Fernandez-del Castillo Carlos , Downes Michael , Evans Ronald M. , Michaelson James , Ferrone Cristina R. , Boucher Yves , Jain Rakesh K.
Published: April 2023

Complete results for GO (Supplementary Table 8) and REACTOME (supplementary Table 9) analysis on differentially expressed genes comparing lisinopril vs. control PDAC tumors
Supplementary Table 11 from Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Authors: Liu Hao , Naxerova Kamila , Pinter Matthias , Incio Joao , Lee Hang , Shigeta Kohei , Ho William W. , Crain Jonathan A. , Jacobson Alex , Michelakos Theodoros , Dias-Santos Daniella , Zanconato Andrea , Hong Theodore S. , Clark Jeffrey W. , Murphy Janet E. , Ryan David P. , Deshpande Vikram , Lillemoe Keith D. , Fernandez-del Castillo Carlos , Downes Michael , Evans Ronald M. , Michaelson James , Ferrone Cristina R. , Boucher Yves , Jain Rakesh K.
Published: April 2023

Complete results for GSEA analysis on GO, BIOCARTA, KEGG, PID, and REACTOME curated gene sets on canonical pathways.
Supplementary Figure S1 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Fig. S1. Estrogen receptor (ER) and progesterone receptor (PR) status of MTC18 and HER2 status of MTC23 and representative Sanger sequencing traces for validated mutations. (a) Representative micrograph of a hematoxylin and eosin-stained slide of case MTC18 with (b) 1% of cells weakly expressing ER and (c) 20% of cells weakly expressing PR. (d) Representative micrograph of case MTC23 (e) lacking HER2 expression by immunohistochemistry but (f) harboring HER2 gene amplification by fluorescence in situ hybridization. (g) Genome plot of MTC23 showing HER2 gene amplification. In the genome plot, smoothed Log2 ratios (y-axis) were plotted according to their genomic positions (x-axis). The red arrow points at the HER2 gene locus. (h) Representative Sanger sequencing traces for validated mutations. Original magnification of micrographs and immunohistochemical staining 200x. Scale bar: 500 μm.
Supplementary materials and figures from T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy
Authors: Wang Tianjiao , Lu Ye , Polk Avery , Chowdhury Pinki , Zamalloa Carlos Murga , Fujiwara Hiroshi , Suemori Koichiro , Beyersdorf Niklas , Hristov Alexandra C. , Lim Megan S. , Bailey Nathanael G. , Wilcox Ryan A.
Published: April 2023

Revised Supplementary Methods Formatted Supplementary Figure 1 Immunophenotype and purity of primary T-cell lymphoma cells. Supplementary Figure 2 Pathway enrichment analysis. Supplementary Figure 3 Gene expression profiling in TCR stimulated T8ML-1. T8ML-1 cells were either unstimulated or activated with anti-CD3/CD28 beads and gene expression examined. Supplementary Figure 4 Activation and cytokine release following TCR engagement. Supplementary Figure 5 Gene expression profiling validation. Supplementary Figure 6 Pharmacologic inhibition of protein kinase C impairs TCR-mediated chemotherapy resistance. Supplementary Figure 7 Immunoflourescent microscopy images of CD3 and ITK following CD3 crosslinking in primary TCL cells (a representative example is shown, n=2). Supplementary Figure 8 Confirmation of shRNA-mediated ITK knockdown in T8ML-1. Supplementary Figure 9 TCR-dependent activation is abrogated following ITK knockdown in T8ML-1 cells. Supplementary Figure 10 Pharmacologic inhibition of ITK or PKC inhibit TCR activation in TCL cells. Supplementary Figure 11 Pharmacologic inhibition of ITK or PKC inhibit NF-κB (p65) activation following TCR engagement in TCL cells. Supplementary Figure 12 TCR activation promotes survival of T8-28 cells in vitro. Supplementary Figure 13 Histologic characterization of T8-28-bearing mice. Supplementary Figure 14 T8-28-bearing mice were treated with vincristine(VCR)/Cyclophosphamide(Cytoxan) and/or ibrutinib, as described in Figure 3. Supplementary Figure 15 GATA-3 expression following TCR activation. Supplementary Figure 16 GATA-3 expression in T8ML-1 cells following ITK or GATA-3 knockdown or GATA-3 overexpression. Supplementary Figure 17 Cell viability in T-cell lymphoma cell lines following GATA-3 knockdown. Supplementary Figure 18 GATA-3 expression was examined by immunohistochemistry in diagnostic lymph node biopsies obtained at the time of diagnosis and after relapse in two PTCL, NOS patients. Supplementary Figure 19 A model depicting ITK- and NF-κB-dependent GATA-3 transcription following TCR engagement. Supplemental Figure 20 TCR engagement confers resistance to vincristine.
Supplementary Table 2 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Authors: Liu Geoffrey , Cuffe Sinead , Liang Shermi , Azad Abul Kalam , Cheng Lu , Brhane Yonathan , Qiu Xin , Cescon David W. , Bruce Jeffrey , Chen Zhuo , Cheng Dangxiao , Patel Devalben , Tse Brandon C. , Laurie Scott A. , Goss Glenwood , Leighl Natasha B. , Hung Rayjean , Bradbury Penelope A. , Seymour Lesley , Shepherd Frances A. , Tsao Ming Sound , Chen Bingshu E. , Xu Wei , Reisman David N.
Published: April 2023

Subgroup prognostic analyses of BRM polymorphisms in adjusted Hazard ratios (95% confidence intervals) - each comparison uses wildtype or double wildtype as the reference category.
Supplemental Table 1 from Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases
Authors: Kotian Shweta , Zhang Lisa , Boufraqech Myriem , Gaskins Kelli , Gara Sudheer Kumar , Quezado Martha , Nilubol Naris , Kebebew Electron
Published: April 2023

Table S1. Summary of mutations present in the thyroid cancer cell lines and expression levels of differentiation markers. The table depicts known mutations in the six thyroid cancer cell lines we have utilized in our study. It also indicates the presence or absence (based on Ct values > 28) of thyroid differentiation markers in normal thyroid tissue, such as sodium-iodide symporter (NIS), thyroglobulin (Tg), and thyroid peroxidase (TPO) based on mRNA expression in these cell lines.
Supplementary Table 1 from Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis
Authors: Al-Azhri Jamila , Zhang Yali , Bshara Wiam , Zirpoli Gary , McCann Susan E. , Khoury Thaer , Morrison Carl D. , Edge Stephen B. , Ambrosone Christine B. , Yao Song
Published: April 2023

Supplementary Table 1. Associations of vitamin D receptor (VDR) expression with tumor histopathological characteristics
Supplemental Figure 5A from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Authors: LaCerte Carl , Ivaturi Vijay , Gobburu Joga , Greer Jacqueline M. , Doyle L. Austin , Wright John J. , Karp Judith E. , Rudek Michelle A.
Published: April 2023

Representative Individual Concentration versus Time Pharmacokinetic Profiles for Total or Unbound lavopiridol Using Bolus (A) or Hybrid (B) Dosing Schemes.
Supplemental Figure 4 from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Authors: LaCerte Carl , Ivaturi Vijay , Gobburu Joga , Greer Jacqueline M. , Doyle L. Austin , Wright John J. , Karp Judith E. , Rudek Michelle A.
Published: April 2023

Supplemental Figure 4. Visual Predictive Check (VPC) for Total or Unbound Flavopiridol Using Bolus or Hybrid Dosing Schemes.
Supplementary Figure 4 from Prognostic Utility of a New mRNA Expression Signature of Gleason Score
Authors: Sinnott Jennifer A. , Peisch Sam F. , Tyekucheva Svitlana , Gerke Travis , Lis Rosina , Rider Jennifer R. , Fiorentino Michelangelo , Stampfer Meir J. , Mucci Lorelei A. , Loda Massimo , Penney Kathryn L.
Published: April 2023

Supplementary Figure 4. Comparison of ROC curves for the nearest shrunken centroid classifier (in solid black line) and the risk score constructed by adding positively associated genes and subtracting negatively associated genes (in dashed line) for the two main analyses: discrimination of 6 vs. 8 and prediction of lethality together with 3+4/4+3 among Gleason 7.
Supplemental Data from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Authors: LaCerte Carl , Ivaturi Vijay , Gobburu Joga , Greer Jacqueline M. , Doyle L. Austin , Wright John J. , Karp Judith E. , Rudek Michelle A.
Published: April 2023

Supplemental Tables 1-5 and upplemental Figure Legends
Supplementary Figure S1 from Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Authors: Sagawa Morihiko , Ohguchi Hiroto , Harada Takeshi , Samur Mehmet K. , Tai Yu-Tzu , Munshi Nikhil C. , Kizaki Masahiro , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

RRM1 and RRM2 expression in a panel of cancer cell lines.
Table S2 from A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Authors: Singh Anurag K. , Winslow Timothy B. , Kermany Mohammad Habiby , Goritz Vincent , Heit Lilia , Miller Austin , Hoffend Nicholas C. , Stein Leighton C. , Kumaraswamy Lalith K. , Warren Graham W. , Bshara Wiam , Odunsi Kunle , Matsuzaki Junko , Abrams Scott I. , Schwaab Thomas , Muhitch Jason B.
Published: April 2023

Supplementary table S2 shows flow cytometry antibodies and dilutions.
Supplementary Tables 1 and 2 from Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Authors: Vilain Ricardo E. , Menzies Alexander M. , Wilmott James S. , Kakavand Hojabr , Madore Jason , Guminski Alexander , Liniker Elizabeth , Kong Benjamin Y. , Cooper Adam J. , Howle Julie R. , Saw Robyn P.M. , Jakrot Valerie , Lo Serigne , Thompson John F. , Carlino Matteo S. , Kefford Richard F. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Supplementary Table 1 - Histomorphological characteristics of tumor samples taken prior to treatment (PRE), early during treatment (EDT) and on disease progression (PROG) in melanoma patients receiving anti-PD-1 therapy Supplementary Table 2 - Immune infiltrate flux from pretreatment value to early during treatment biopsies (fold change).
Supplementary Notes and supplementary figures 1 and 2 from Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Authors: Vilain Ricardo E. , Menzies Alexander M. , Wilmott James S. , Kakavand Hojabr , Madore Jason , Guminski Alexander , Liniker Elizabeth , Kong Benjamin Y. , Cooper Adam J. , Howle Julie R. , Saw Robyn P.M. , Jakrot Valerie , Lo Serigne , Thompson John F. , Carlino Matteo S. , Kefford Richard F. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Supplementary Figure 1 and 2. Characteristics of tumour tissue sampled pre-treatment (PRE), early during treatment (EDT) and on acquisition of PD-1 inhibitor resistance (PROG).
Supplementary Table 3 from Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy
Authors: Bloch Orin , Lim Michael , Sughrue Michael E. , Komotar Ricardo J. , Abrahams John M. , O'Rourke Donald M. , D'Ambrosio Anthony , Bruce Jeffrey N. , Parsa Andrew T.
Published: April 2023

Proportional Hazards Model of Overall Survival
Supplementary Figure 1 from Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy
Authors: Bloch Orin , Lim Michael , Sughrue Michael E. , Komotar Ricardo J. , Abrahams John M. , O'Rourke Donald M. , D'Ambrosio Anthony , Bruce Jeffrey N. , Parsa Andrew T.
Published: April 2023

Trial Screening and Enrollment
Supplementary Appendix from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Authors: Coutré Steven E. , Furman Richard R. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff , Jones Jeffrey , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Johnson Amy J. , Tran Anh , Zhou Cathy , Bilotti Elizabeth , James Danelle F. , Byrd John C. , O'Brien Susan
Published: April 2023

Supplementary Table S1: Patient disposition; Supplementary Table S2: Summary of adverse events; Supplementary Table S3: Response improvement and durability; Supplementary Table S4: Best response in patients who achieved PR with lymphocytosis; Supplementary Table S5: Outcomes by cytogenetics (FISH) in the relapsed/refractory population; Supplementary Figure 1: Outcomes by cytogenetics (FISH) in the relapsed refractory population. (A) Progression-free survival and (B) overall survival in cytogenetic subgroups in patients with R/R CLL/SLL.
Supplementary Data from Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
Authors: McCormick Aiste , Donoghue Peter , Dixon Michelle , O'Sullivan Richard , O'Donnell Rachel L. , Murray James , Kaufmann Angelika , Curtin Nicola J. , Edmondson Richard J.
Published: April 2023

Supplementary Table ST1. Patient characteristics for primary culture samples divided by NHEJ status. Supplementary figure S1. Predictors of NHEJ function A. pDNA-PKcs foci 1 hour after 2 Gy IR normalised to untreated controls. Foci were counted across 3 fields of view in > 50 cells for each condition.
Supplementary Table S5 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Genomic rearrangements in case 9-P and S02404
FigureS2 from Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis
Authors: Ueda Shigeto , Saeki Toshiaki , Osaki Akihiko , Yamane Tomohiko , Kuji Ichiei
Published: April 2023

Baseline relations between FDG, FMISO, and metabolic response: Scatter diagrams show the relationship between FDG and FMISO in both luminal breast cancer (A) (r = 0.54; 95% CI, 0.13-0.79; p = 0.01) and triple-negative breast cancer (B) (r = 0.61; 95% CI â^'0.25-0.93; p = 0.1). Open circles are metabolic responders and filled circles are non-responders.
Supplementary Table S3 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

CD274 copy number in SCLCs
FigureS1 from Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis
Authors: Ueda Shigeto , Saeki Toshiaki , Osaki Akihiko , Yamane Tomohiko , Kuji Ichiei
Published: April 2023

Survival impact of FDG-PET metabolic response Kaplan-Meier survival analysis demonstrated that metabolic responders (n = 18) as measured by serial FDG-PET/CT scans with a cut-off value of 20% reduction of SUVmax, had a favorable outcome of overall survival compared to non-responders (n = 10) (log-rank test, p = 0.1). Multivariate analysis using the COX regression model demonstrated hormonal receptor negativity (HR 7.6, 95%CI 1.0-57.2, p = 0.04) as an independent predictor of poor survival when compared to PET non-responders (HR 7.2, 95%CI 0.9-57.6, p = 0.06) and distant metastasis (HR 2.5, 95%CI 0.4-14.9, p = 0.3).
Supplementary Fig S5 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Analysis of immune cell signatures
Vismodegib CRD from Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies
Authors: Spilker Mary E. , Chen Xiaoying , Visswanathan Ravi , Vage Chandra , Yamazaki Shinji , Li Gang , Lucas Judy , Bradshaw-Pierce Erica L. , Vicini Paolo
Published: April 2023

Vismodegib CRD Calculation Details
Supplementary Fig S4 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Chromosome 9p24, clinical and pathological features of SCLC.
Nomenclature of PK Metrics from Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies
Authors: Spilker Mary E. , Chen Xiaoying , Visswanathan Ravi , Vage Chandra , Yamazaki Shinji , Li Gang , Lucas Judy , Bradshaw-Pierce Erica L. , Vicini Paolo
Published: April 2023

Description of common pharmacokinetic parameters used in the CRD calculations.
Supplementary Material S2 from How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software
Authors: Dugué Audrey Emmanuelle , Pulido Marina , Chabaud Sylvie , Belin Lisa , Gal Jocelyn
Published: April 2023

SAS INPUT AND OUTPUT
Supplementary Material S1 from How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software
Authors: Dugué Audrey Emmanuelle , Pulido Marina , Chabaud Sylvie , Belin Lisa , Gal Jocelyn
Published: April 2023

DATASET
Table S1-S3 from Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value
Authors: Mazzaschi Giulia , Madeddu Denise , Falco Angela , Bocchialini Giovanni , Goldoni Matteo , Sogni Francesco , Armani Giovanna , Lagrasta Costanza Annamaria , Lorusso Bruno , Mangiaracina Chiara , Vilella Rocchina , Frati Caterina , Alfieri Roberta , Ampollini Luca , Veneziani Michele , Silini Enrico Maria , Ardizzoni Andrea , Urbanek Konrad , Aversa Franco , Quaini Federico , Tiseo Marcello
Published: April 2023

Table S1. Antibodies for Immunohistochemistry; Table S2. Magnitude of Sampling; Table S3. Magnitude of Sampling
Suppl. Figure 1 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Authors: Zeng Qinghai , Liu Jianye , Cao Peiguo , Li Jingjing , Liu Xiaoming , Fan Xiaojun , Liu Ling , Cheng Yan , Xiong Wei , Li Jigang , Bo Hao , Zhu Yuxing , Yang Fei , Hu Jun , Zhou Ming , Zhou Yanhong , Zou Qiong , Zhou Jianda , Cao Ke
Published: April 2023

REDD1 regulates cell proliferation, apoptosis, and autophagy in EJ and BIU87 cells. (A-B) Western blot analysis of REDD1, C-caspase 3, c-PARP, LC3-I/II, and EEF2K in EJ cells transfected with REDD1-shRNA (sh-3), and BIU87 cells transfected with REDD1 over-expression plasmid. (C) Cell proliferation was determined in EJ and BIU87 cells using the CCK-8 method. (D) Expression of the autophagy marker LC3B was detected by immunofluorescence, and analyzed with flow cytometry. (E) Apoptosis of EJ and BIU87 cells with modulation of REDD1 expression was detected by flow cytometric analysis of annexin V and propidium iodide staining. (F) Cell cycle in EJ and BIU87 cells was analyzed by flow cytometry analysis. Proliferation index (PI) = (S+G2/M)/(S+G2/M+G0/G1). (G-H) The levels of p-AKT, AKT, p-mTOR, mTOR, p-S6K1, S6K1, EEF2K, and LC3-I/II were examined by western blot. The time point of "o min" was identified beginning at 24 hours after sh-REDD1 or REDD1 plasmid transfecting. ****P<0.0001, *P<0.05.
Supplementary table 2 from BRCA1-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
Authors: Lips Esther H. , Debipersad Rashmie D. , Scheerman Caroline E. , Mulder Lennart , Sonke Gabe S. , van der Kolk Lizet E. , Wesseling Jelle , Hogervorst Frans B.L. , Nederlof Petra M.
Published: April 2023

This file shows the significant regions (highlighted in supplementary figure 1) for the comparison B1mutER+ versus SporER+. Subsequently the weighted average frequency in B1mutER+, in SporER+ and the difference between both groups is shown. The last two columns show respectively the p-value and the false discovery rate (q-bound).
Supplement from A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
Authors: Rasche Leo , Menoret Emmanuelle , Dubljevic Valentina , Menu Eline , Vanderkerken Karin , Lapa Constantin , Steinbrunn Torsten , Chatterjee Manik , Knop Stefan , Düll Johannes , Greenwood Deanne L. , Hensel Frank , Rosenwald Andreas , Einsele Hermann , Brändlein Stephanie
Published: April 2023

Supplementary Table 1 Figure S1A, S1B
Figure S7 from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

Fold change in MMP1 expression in HPV- cell lines, as determined by qRT-PCR
Supplementary Table 2 from Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Balasubramanian Sriram , Saiya-Cork Kamlai , Shedden Kerby , Hu Nan , Malek Sami N.
Published: April 2023

Biomarkers, gene mutations and ibrutinib IC50 values
Supplementary Table 1 from Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Balasubramanian Sriram , Saiya-Cork Kamlai , Shedden Kerby , Hu Nan , Malek Sami N.
Published: April 2023

Patient Characteristics; treatments, response types; biomarkers
Supplemental Table 2 from TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Jeselsohn Rinath , Barry William T. , Migliaccio Ilenia , Biagioni Chiara , Zhao Jin , De Tribolet-Hardy Jonas , Guarducci Cristina , Bonechi Martina , Laing Naomi , Winer Eric P. , Brown Myles , Leo Angelo Di , Malorni Luca
Published: April 2023

Cox proportional hazards analyses
Figure S1 from Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Authors: Schøler Lone V. , Reinert Thomas , Ørntoft Mai-Britt W. , Kassentoft Christine G. , Árnadóttir Sigrid S. , Vang Søren , Nordentoft Iver , Knudsen Michael , Lamy Philippe , Andreasen Ditte , Mortensen Frank V. , Knudsen Anders R. , Stribolt Katrine , Sivesgaard Kim , Mouritzen Peter , Nielsen Hans J. , Laurberg Søren , Ørntoft Torben F. , Andersen Claus L.
Published: April 2023

Detection of ctDNA in pre-operative plasma samples according to stage.
Supplemental Figure 2 from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Authors: Mehrotra Shailly , Gopalakrishnan Mathangi , Gobburu Jogarao , Ji Jiuping , Greer Jacqueline M. , Piekarz Richard , Karp Judith E. , Pratz Keith W. , Rudek Michelle A.
Published: April 2023

Correlation between objective response rate (ORR) and overall survival (OS)
Supplemental Figure 1A from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Authors: Mehrotra Shailly , Gopalakrishnan Mathangi , Gobburu Jogarao , Ji Jiuping , Greer Jacqueline M. , Piekarz Richard , Karp Judith E. , Pratz Keith W. , Rudek Michelle A.
Published: April 2023

Relationship between AUC and Cmax after single dose (A)
Table S1 from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Authors: Richard Corentin , Fumet Jean-David , Chevrier Sandy , Derangère Valentin , Ledys Fanny , Lagrange Aurélie , Favier Laure , Coudert Bruno , Arnould Laurent , Truntzer Caroline , Boidot Romain , Ghiringhelli François
Published: April 2023

Table S1
Figure S1 from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Authors: Richard Corentin , Fumet Jean-David , Chevrier Sandy , Derangère Valentin , Ledys Fanny , Lagrange Aurélie , Favier Laure , Coudert Bruno , Arnould Laurent , Truntzer Caroline , Boidot Romain , Ghiringhelli François
Published: April 2023

Figure S1 Figure S1: (A-B) Kaplan-Meier estimates for progression-free survival (A) and overall survival (B); patients were stratified according to their RECIST response: progression-disease (PD, in red), stabledisease (SD, in blue), and partial-response (PR, in yellow). (C-D) Kaplan-Meier estimates for progression-free survival (C) and overall survival (D); patients were stratified according to their PD-L1 expression: low expression (in red) or high expression (in blue). High and low expressions were determined according to POPLAR study. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001; ns: not significant.
Supplementary Data from Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project
Authors: Sohn Bo Hwa , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Shim Jae-Jun , Lee Keun-Wook , Kim Eui Hyun , Yim Sun Young , Lee Sang Ho , Cheong Jae-Ho , Jeong Woojin , Cho Jae Yong , Kim Joohee , Chae Jungsoo , Lee Jeeyun , Kang Won Ki , Kim Sung , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

7 figures and 7 Tables
Figure S7 from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

Expression of G-CSF and existence of MDSC in TRL-positive cervical cancer/endometrial cancer.
Table S1 from Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma
Authors: Hausner Sven H. , Bold Richard J. , Cheuy Lina Y. , Chew Helen K. , Daly Megan E. , Davis Ryan A. , Foster Cameron C. , Kim Edward J. , Sutcliffe Julie L.
Published: April 2023

Shows the quality assurance release criteria for [18F]αvβ6-BP
Supplemental Table 1. from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Authors: Somlo George , Frankel Paul H. , Arun Banu K. , Ma Cynthia X. , Garcia Agustin A. , Cigler Tessa , Cream Leah V. , Harvey Harold A. , Sparano Joseph A. , Nanda Rita , Chew Helen K. , Moynihan Timothy J. , Vahdat Linda T. , Goetz Matthew P. , Beumer Jan H. , Hurria Arti , Mortimer Joanne , Piekarz Richard , Sand Sharon , Herzog Josef , Van Tongeren Lily R. , Ferry-Galow Katherine V. , Chen Alice P. , Ruel Christopher , Newman Edward M. , Gandara David R. , Weitzel Jeffrey N.
Published: April 2023

Best response in phase I* and phase II
Supplementary Tables (S1-S2) from Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling
Authors: Wu Geyan , Cao Lixue , Zhu Jinrong , Tan Zhanyao , Tang Miaoling , Li Ziwen , Hu Yameng , Yu Ruyuan , Zhang Shuxia , Song Libing , Li Jun
Published: April 2023

Supplementary Tables to support primary figures.
Supplementary Figures from Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling
Authors: Wu Geyan , Cao Lixue , Zhu Jinrong , Tan Zhanyao , Tang Miaoling , Li Ziwen , Hu Yameng , Yu Ruyuan , Zhang Shuxia , Song Libing , Li Jun
Published: April 2023

Supplementary Figure 1 shows that loss of RBMS3 correlates with chemoresistance in pan-cancer. Supplementary Figure 2 shows that dysregulation of RBMS3 is involved in chemoresistance in EOC in vivo. Supplementary Figure 3 shows that ablation of RBMS3 confers resistance of EOC cells to cisplatin in vitro. Supplementary Figure 4 shows that loss of RBMS3 activates Wnt/β-catenin signaling. Supplementary Figure 5 shows that RBMS3 stabilizes multiple negative regulators in Wnt/β-catenin cascade. Supplementary Figure 6 shows that miR-126-5p directly represses expression of multiple negative regulators of Wnt/β-Catenin pathway. Supplementary Figure 7 shows that blocking CBP/β-catenin signaling confers chemosensitivity to RBMS3-deleted cells. Supplementary Figure 8 shows that combined PRI-724 sensitizes RBMS3-deleted EOC to CDDP therapy.
Supplementary Data from Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry
Authors: Carvajal-Hausdorf Daniel E. , Patsenker Jonathan , Stanton Kelly P. , Villarroel-Espindola Franz , Esch Amanda , Montgomery Ruth R. , Psyrri Amanda , Kalogeras Konstantine T. , Kotoula Vassiliki , Foutzilas George , Schalper Kurt A. , Kluger Yuval , Rimm David L.
Published: April 2023

supp figure legends
Supplementary Figure Legends from Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling
Authors: Wu Geyan , Cao Lixue , Zhu Jinrong , Tan Zhanyao , Tang Miaoling , Li Ziwen , Hu Yameng , Yu Ruyuan , Zhang Shuxia , Song Libing , Li Jun
Published: April 2023

Supplementary Figure Legends to support primary figures.
Supplementary Data from Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry
Authors: Carvajal-Hausdorf Daniel E. , Patsenker Jonathan , Stanton Kelly P. , Villarroel-Espindola Franz , Esch Amanda , Montgomery Ruth R. , Psyrri Amanda , Kalogeras Konstantine T. , Kotoula Vassiliki , Foutzilas George , Schalper Kurt A. , Kluger Yuval , Rimm David L.
Published: April 2023

supp info and figures
Supplementary Data - Figure 2 from SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer
Authors: Tao Zhen , McCall Neal S. , Wiedemann Norbert , Vuagniaux Grégoire , Yuan Zhiyong , Lu Bo
Published: April 2023

Analysis of tumor tissues demonstrates effective CD8 depletion. Tumors harvested from mice treated with anti-CD8 antibody (right) in Figure 4 were analyzed for CD8 by flow cytometry with tumors treated with ART alone (left) shown for reference. Tumors were harvested at the same time point as other flow cytometry experiments, day 12 after ART.
Supplementary Materials and Methods from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary Materials and Methods
Supplemental Table 4 from CD103 and Intratumoral Immune Response in Breast Cancer
Authors: Wang Zhi-Qiang , Milne Katy , Derocher Heather , Webb John R. , Nelson Brad H. , Watson Peter H.
Published: April 2023

Supplemental Table 4. Univariate and multivariate analyses of clinical parameters and eCD103 or eCD8 status and their relation with recurrence free survival and overall survival in all cases.
Figure S3 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary Figure
Supplementary Figure Legends from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types
Authors: Chüeh Anderly C. , Tse Janson W.T. , Dickinson Michael , Ioannidis Paul , Jenkins Laura , Togel Lars , Tan BeeShin , Luk Ian , Davalos-Salas Mercedes , Nightingale Rebecca , Thompson Matthew R. , Williams Bryan R.G. , Lessene Guillaume , Lee Erinna F. , Fairlie Walter D. , Dhillon Amardeep S. , Mariadason John M.
Published: April 2023

Supplementary Figure Legends
Supplementary Video S1 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Authors: Tanaka Noriaki , Patel Ameeta A. , Tang Lin , Silver Natalie L. , Lindemann Antje , Takahashi Hideaki , Jaksik Roman , Rao Xiayu , Kalu Nene N. , Chen Tseng-Cheng , Wang Jiping , Frederick Mitchell J. , Johnson Faye , Gleber-Netto Frederico O. , Fu Siqing , Kimmel Marek , Wang Jing , Hittelman Walter N. , Pickering Curtis R. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Live cell imaging of histone-H2B-RFP expressing PCI13-G245D cells in the presence of AZD1775.
Table S6 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Authors: Audenet François , Isharwal Sumit , Cha Eugene K. , Donoghue Mark T.A. , Drill Esther N. , Ostrovnaya Irina , Pietzak Eugene J. , Sfakianos John P. , Bagrodia Aditya , Murugan Paari , Dalbagni Guido , Donahue Timothy F. , Rosenberg Jonathan E. , Bajorin Dean F. , Arcila Maria E. , Hechtman Jaclyn F. , Berger Michael F. , Taylor Barry S. , Al-Ahmadie Hikmat , Iyer Gopa , Bochner Bernard H. , Coleman Jonathan A. , Solit David B.
Published: April 2023

Characteristics of the patients included for the matched-pairs analysis of bladder recurrence after radical nephroureterectomy (RNU).
Table S2 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Authors: Audenet François , Isharwal Sumit , Cha Eugene K. , Donoghue Mark T.A. , Drill Esther N. , Ostrovnaya Irina , Pietzak Eugene J. , Sfakianos John P. , Bagrodia Aditya , Murugan Paari , Dalbagni Guido , Donahue Timothy F. , Rosenberg Jonathan E. , Bajorin Dean F. , Arcila Maria E. , Hechtman Jaclyn F. , Berger Michael F. , Taylor Barry S. , Al-Ahmadie Hikmat , Iyer Gopa , Bochner Bernard H. , Coleman Jonathan A. , Solit David B.
Published: April 2023

Characteristics of the patients with mismatch repair-deficient UTUC tumors.